Teva and OncoGenex start second Phase 3 trial

Teva Pharmaceuticals (NASDAQ: TEVA) and OncoGenex Pharmaceuticals (NASDAQ: OGXI) initiated their second pivotal trial evaluating their custirsen drug as a first line therapy for the treatment of castrate-resistant prostate cancer (CRPC). The Synergy trial will be conducted in some 125 cancer centres with designated recruitment of 800 men with metastatic CRPC, who have disease progression [...]

RBC Capital downgrades Angiotech

Citing the risks of a debt restructuring at Angiotech Pharmaceuticals (NASDAQ:ANPI; TSX: ANP), RBC Capital Markets has downgraded the stock to “underperform” from “sector perform” and cut the target price to 50 cents (U.S.) from $1.50. The stock closed at 62 cents on Wednesday. Analyst Doug Miehm writes that while there are many promising products [...]

Warburg to invest up to $35 million in Protox

Two Warburg Pincus funds have agreed to invest up to $35 million in Protox Therapeutics (TSX:PRX), consisting of an initial tranche of $10 million and an additional tranche of $25 million, resulting in the funds having majority stake in Protox. “Warburg Pincus’ impressive track record of building substantial shareholder value, providing access to growth capital, [...]

Ondine to consolidate shares and change name

Ondine Biopharma (TSX,AIM:OBP) plans to consolidate its outstanding common stock on a basis of 15-for-one and change its name to Ondine Biomedical Inc. to more accurately reflect the nature of its operations. There would be about 8,453,042 common shares outstanding after the consolidation, compared with 126,796,145 currently. Stock options and warrants outstanding would be adjusted [...]

Lorus sets $5.5 million rights offering

Lorus Therapeutics (TSX:LOR) has filed with securities regulators in Canada for a rights offering that would give shareholders one right for each common share held as of Oct. 12, 2010. Each two rights will entitle holders to purchase one unit of Lorus at a price of $1.11 each. Each unit consists of one common share and [...]

Bioniche links future disclosure to trading activity

Bioniche Life Sciences (TSX:BNC) expects to make a statement within the next several weeks about its Phase 3 clinical trial with its bladder cancer drug Urocidin. The company made the disclosure in response to recent activity in shares, noting that it believes the jump in volume and share price was driven by expectations of a statement [...]

MethylGene gets two U.S. patents

MethylGene (TSX:MYG) has been granted two composition of matter patents from the U.S. Patent and Trademark Office for the company’s multi-targeted kinase inhibitor for oncology, MGCD265, which is currently in clinical development. “Solidifying our proprietary position is strategically important as we continue to evaluate MGCD265 in solid tumour cancers and work toward realizing the full [...]

Wex may modify cancer pain trial

A data monitoring committee analyzing Wex Pharmaceuticals’ (TSX:WXI) Phase 3 clinical trial of  Tetrodotoxin (TTX) in patients with cancer-related pain has  found no safety concerns to stop or modify the trial based on an interim analysis of 60 patients. However, the committee informed Wex that the trial was “unlikely to demonstrate a clinically meaningful treatment-effect [...]

OncoGenex starts prostate cancer trial

OncoGenex Pharmaceuticals (NASDAQ:OGXI) has initiated a randomized, investigator-sponsored Phase 2 trial of its OGX-427 drug candidate in men with metastatic prostate cancer. The study will enrol up to 72 men who have minimally symptomatic or asymptomatic advanced prostate cancer and who have not yet received chemotherapy. It is designed to determine the potential benefit of [...]

Angiotech provides follow-up Taxus trial data

Angiotech Pharmaceuticals (TSX:ANP; NASDAQ:ANPI) and its corporate partner, Boston Scientific (NYSE:BSX),  have released three-year follow-up data from the Horizons AMI trial designed to determine the safety and efficacy of the Taxus Express paclitaxel-eluting coronary stent, compared with bare-metal stents, in patients having a heart attack. “Follow-up data from the Horizons AMI trial continue to show [...]

Next Page »